Daiichi Sankyo gets US patent office to restart review of Seagen patent
Daiichi Sankyo is going back after Seagen in the latest bout of patent infringement accusations.
The Japanese pharma announced Friday that the US Patent and Trademark Office (PTO) has agreed to the company’s request to restart a post-grant review of a Seagen patent.
A post-grant review (PGR) is when the patent office’s board — called the Patent Trial and Appeal Board — examines at least one claim from an existing patent in a bid to determine if that claim is capable of being patented.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.